Tomas Cihlar
Overview
Explore the profile of Tomas Cihlar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
9191
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Woolsey C, Cross R, Chu V, Prasad A, Agans K, Borisevich V, et al.
Sci Adv
. 2025 Mar;
11(11):eadw0659.
PMID: 40085692
Obeldesivir (ODV; GS-5245) is an orally administered ester prodrug of the parent nucleoside GS-441524 that has broad spectrum antiviral activity inhibiting viral RNA-dependent RNA polymerases. We recently showed that ODV...
2.
Nystrom K, Trybala E, Said J, Roth A, Patzi Churqui M, Karmander A, et al.
Infect Dis (Lond)
. 2025 Feb;
:1-8.
PMID: 39973341
Background: Tick-borne encephalitis (TBE) is a neurological disease caused by the tick-borne encephalitis virus (TBEV). Despite available vaccines, breakthrough infections occur, some fatal. Objectives: As no antiviral therapy for TBE...
3.
Irrinki A, Kaur J, Randhawa B, McFadden R, Snyder C, Truong H, et al.
PLoS Pathog
. 2025 Feb;
21(2):e1012874.
PMID: 39913544
Despite suppressive antiretroviral therapy (ART), HIV-1 persists in latent reservoirs that seed new HIV infections if ART is interrupted, necessitating lifelong therapy for people with HIV. Activation of latent HIV...
4.
Cross R, Woolsey C, Prasad A, Borisevich V, Agans K, Deer D, et al.
Nat Med
. 2025 Jan;
PMID: 39805309
The recent outbreak of Marburg virus (MARV) in Rwanda underscores the need for effective countermeasures against this highly fatal pathogen, with case fatality rates reaching 90%. Currently, no vaccines or...
5.
Zumbrun E, Garvey C, Wells J, Lynn G, Van Tongeren S, Steffens J, et al.
Viruses
. 2025 Jan;
16(12.
PMID: 39772240
Ebola virus (EBOV) causes severe disease in humans, with mortality as high as 90%. The small-molecule antiviral drug remdesivir (RDV) has demonstrated a survival benefit in EBOV-exposed rhesus macaques. Here,...
6.
Demarest J, Draghia-Akli R, Cihlar T, Bradley K, Young J, Chandra R, et al.
Nat Rev Drug Discov
. 2024 Dec;
24(2):151-152.
PMID: 39622985
No abstract available.
7.
Siegel D, Hui H, Pitts J, Vermillion M, Ishida K, Rautiola D, et al.
J Med Chem
. 2024 Jul;
67(15):12945-12968.
PMID: 39018526
Acute respiratory viral infections, such as pneumovirus and respiratory picornavirus infections, exacerbate disease in COPD and asthma patients. A research program targeting respiratory syncytial virus (RSV) led to the discovery...
8.
Martinez D, Moreira F, Catanzaro N, Diefenbacher M, Zweigart M, Gully K, et al.
Sci Transl Med
. 2024 May;
16(748):eadj4504.
PMID: 38776389
Despite the wide availability of several safe and effective vaccines that prevent severe COVID-19, the persistent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that...
9.
Cross R, Woolsey C, Chu V, Babusis D, Bannister R, Vermillion M, et al.
Science
. 2024 Mar;
383(6688):eadk6176.
PMID: 38484056
Obeldesivir (ODV, GS-5245) is an orally administered prodrug of the parent nucleoside of remdesivir (RDV) and is presently in phase 3 trials for COVID-19 treatment. In this work, we show...
10.
Mulato A, Lansdon E, Aoyama R, Voigt J, Lee M, Liclican A, et al.
Antimicrob Agents Chemother
. 2024 Feb;
68(4):e0137323.
PMID: 38380945
Protease inhibitors (PIs) remain an important component of antiretroviral therapy for the treatment of HIV-1 infection due to their high genetic barrier to resistance development. Nevertheless, the two most commonly...